RxDoctor Payments Data

Rachel Hobbs, MD

Family Medicine · Layton, UTNPI 1275519126

Payments from drug & device makers

$7,638in general payments, 2019–2025

Across 496 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$938
  • Lilly USA, LLC$831
  • Pfizer$647
  • Boehringer Ingelheim$596
  • Amgen$466
  • GSK$458
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$7,53899%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)64$938
Lilly USA, LLC62$831
Pfizer53$647
Boehringer Ingelheim30$596
Amgen33$466
GSK29$458
Astellas Pharma US Inc16$318
AstraZeneca19$315
Johnson & Johnson19$277
Amarin Pharma, Inc.19$263
E.r. Squibb & Sons, L.L.C.14$193
Merck11$167
Sanofi-aventis U.S. LLC11$156
Dynavax Technologies Corporation9$137
Biogen6$103
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$99
Inspire Medical Systems, Inc.5$90
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$82
Tris Pharma Inc1$80
Sumitomo Pharma America, Inc.5$78
Daiichi Sankyo Inc.4$78
Axsome Therapeutics, Inc.4$68
Dexcom, Inc.3$66
Cranial Technologies, Inc4$66
Takeda Pharmaceuticals U.S.A., Inc.3$65
Biohaven Pharmaceutical Holding Company Ltd.3$64
Novo Nordisk4$61
Neurocrine Biosciences, Inc.3$54
Viatris Specialty LLC2$49
Idorsia Pharmaceuticals US Inc3$45
Exact Sciences3$44
Novartis3$43
Mylan Specialty L.p.2$43
Biohaven Pharmaceuticals, Inc.3$43
Phathom Pharmaceuticals, Inc.3$39
Shire North American Group Inc3$38
Ultragenyx Pharmaceutical Inc.2$37
Organon3$35
Genentech USA, Inc.2$31
Adlon Therapeutics L.p.2$31
Lucid Diagnostics Inc.2$31
Innovation Technologies Inc1$30
Sunovion Pharmaceuticals Inc.2$29
Edwards Lifesciences1$23
Abbott1$23
Vanda Pharmaceuticals Inc.1$19
BD1$17
Almatica Pharma LLC1$17
Shield Therapeutics Inc1$16
Jazz Pharmaceuticals Inc.1$16
BETA Bionics, Inc.1$15
Seqirus USA Inc1$15
Bayer1$15
Avanir Pharmaceuticals, Inc.1$14
Ironshore Pharmaceuticals Inc.1$14
Neurelis, Inc.1$13
Alkermes, Inc.1$12
Kowa Pharmaceuticals America, Inc.1$12
Teva Pharmaceuticals USA, Inc.1$12

How this compares

$7,638 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$183,050
Medicare patients
251
Services billed
6,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate37$45,876
OzempicSemaglutide13$33,578
MyrbetriqMirabegron19$24,448
EliquisApixaban19$23,985
XareltoRivaroxaban18$21,677
MounjaroTirzepatide18$21,221
JanumetSitagliptin Phos/Metformin Hcl26$18,852
Liothyronine Sodium386$13,552
TrulicityDulaglutide12$13,311
LinzessLinaclotide13$8,648
Levothyroxine Sodium574$5,019
Duloxetine Hcl91$4,006
SymbicortBudesonide/Formoterol Fumarate13$3,782
Atorvastatin Calcium384$3,364
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$167$64,72963 claims
Lilly USA, LLCMounjaro, Trulicity$831$34,53230 claims
Novo NordiskOzempic$61$33,57813 claims
Astellas Pharma US IncMyrbetriq$318$24,44819 claims
PfizerEliquis$647$23,98519 claims
Johnson & JohnsonXarelto$277$21,67718 claims
AbbVieLinzess$938$8,64813 claims
AstraZenecaSymbicort$315$3,78213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.

Other family medicine in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →